Market Overview

Northwest Biotherapeutics In Recovery From Thursday Debacle?

Related NWBO
NW Bio Reports Release of New Data for Phase I Trial of DCVax-Direct: 27 of 39 Patients Still Alive at Up to 18 Months After First Injection
NW Bio Offers 'Promising Survival Data' in 51 GBM Patients Treated with DCVAX-L: Data Demonstrated Substantially Longer-Than-Expected Survival

Northwest Biotherapeutics (NASDAQ: NWBO) have seen a recovery, after shares plunged when Dr. Aman Buzdar (an oncologist who serves as the VP of clinical research at MD Anderson) criticized the company's publicity tactics.

"The company is trying to create tremendous hype about its product," the doctor, Aman Buzdar, told's Adam Feuerstein. In effect Buzdar accused Northwest of cherry-picking data from the incomplete trial and presenting that to investors.

Northwest responded Friday, saying Feuerstein is "trying to smear the company," adding that the item represents "not even the semblance of professional analysis."

Northwest said it had carefully described information from the trials as "interim data."

Buzdar, an oncologist, is vice president of clinical research at MD Anderson, a unit of the University of Texas system. A phase I/II clinical trial of Northwest BioNorthwest bio's cancer drug DCVax-Direct is being run by MD Anderson and is funded by Northwest.

Northwest shares traded recently at $7.62, up 6.1 percent.

Editor's note: This story was updated from the original post. Dr. Aman Buzdar has no involvement in the clinical trials conducted by Northwest Biotherapeutics.

Posted-In: Aman Buzdar The StreetNews Events


Related Articles (NWBO)

Get Benzinga's Newsletters